ERBB3 and pancreatic neoplasm: suggested that standard‐of‐care chemotherapy regimens, such as GnP, increase the expression and activation of insulin‐like growth factor receptor 1 and HER3 in pancreatic cancer cells, rendering the cells tolerant to cytotoxic therapies [34].